- Trial phase
- Phase 2/3
- Time to market
- If successful through Phase 2/3, potential launch is estimated around 2030 per earlier BioMarin guidance, though the timeline depends on Phase 2/3 results and regulatory interactions.
- Why 4/10
- The next hard, dated catalyst is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given, more than 12 months from today). With no near-term binary catalyst and BMN 333 being one of several pipeline assets at a diversified rare-disease company with nine marketed products, the impact score is a default 4.
The next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.
Price Chart
Executive Summary
BMN 333 is BioMarin's investigational long-acting C-type natriuretic peptide (CNP) for achondroplasia, designed as a once-weekly subcutaneous injection versus the daily injections required by its predecessor Voxzogo (vosoritide). Phase 1 data presented at ENDO 2026 showed favorable safety and supported weekly dosing. A registration-enabling Phase 2/3 study (NCT07441876) began enrolling in April 2026 and continues on track, with dose-response data from the dose-finding segment expected in 2027. The competitive landscape shifted significantly in February 2026 when Ascendis Pharma received FDA approval for Yuviwel (navepegritide), the first once-weekly CNP for achondroplasia. BMN 333 is a mid-to-late-stage pipeline asset at a diversified rare-disease company with nine marketed products and over $1 billion in quarterly revenue, meaning its impact on BMRN's share price is moderated by the broader portfolio and the distant timeline to commercialization.
How It Works
BMN 333 is a long-acting version of BioMarin's existing drug Voxzogo (vosoritide). Achondroplasia, the most common form of dwarfism, is caused by a genetic mutation that over-suppresses bone growth. BMN 333 is a C-type natriuretic peptide (CNP) that counteracts this suppression and stimulates bone growth. It is designed as a prodrug that slowly releases the active medication over a week, so patients would need only one injection per week instead of a daily shot. The drug uses a biodegradable hydrogel technology to achieve this extended release.
Trial Status
Phase 1 single ascending dose study in healthy adults completed with favorable safety and PK supporting weekly dosing. Phase 2/3 registration-enabling study (NCT07441876) began enrolling in April 2026, is a randomized, active-controlled, operationally seamless trial comparing BMN 333 against vosoritide in treatment-naive children with achondroplasia. The Phase 2 dose-finding segment is ongoing; dose-response data expected in 2027. Primary completion of the full study is estimated around June 2029.
The Two-Sided Case
Upcoming Catalysts
- Dose-response data from the Phase 2/3 dose-finding segment expected in 2027 (no specific date given)
- PDUFA action date of May 30, 2027 for VOXZOGO in hypochondroplasia (a separate BioMarin catalyst)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report